✦ LIBER ✦

Optimizing the treatment of metastatic breast cancer

✍ Scribed by Julie R. Gralow

Publisher: Springer US
Year: 2005
Tongue: English
Weight: 193 KB
Volume: 89
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-005-0143-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of HER2 status: For the treat

Evaluation of HER2 status: For the treatment of metastatic breast cancers by humanized anti-HER2 monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab)

✍ Shinobu Umemura; Goi Sakamoto; Hironobu Sasano; Hitoshi Tsuda; Futoshi Akiyama; 📂 Article 📅 2001 🏛 Springer Japan 🌐 English ⚖ 998 KB

Optimizing ixabepilone treatment schedul

Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer

✍ Nancy Egerton 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 265 KB

Herceptin in the treatment of metastatic

Herceptin in the treatment of metastatic breast cancer

✍ G. Konecny; M. Untch; M. Pegram 📂 Article 📅 1999 🏛 Springer 🌐 German ⚖ 120 KB

Breast cancer in elderly women. Optimizi

Breast cancer in elderly women. Optimizing the treatment

✍ Roberto Gennari; Riccardo A. Audisio 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 201 KB

Treatment of metastatic breast cancer wi

Treatment of metastatic breast cancer with aminoglutethimide

✍ R. F. Asbury; R. F. Bakemeier; E. Fölsch; C. S. McCune; E. Savlov; J. M. Bennett 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

Oral medroxyprogesterone in the treatmen

Oral medroxyprogesterone in the treatment of metastatic breast cancer

✍ Takuma Nemoto; Jashbha1 Patel; Dutzu Rosner; Thomas L. Dao 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

In 47 postmenopausal women with evaluable breast cancer, oral medroxyprogesterone acetate (MPA) was given at a daily dose level of 400 mg. Patients with negative estrogen receptors, poor performance status , or nonresponse to previous endocrine therapy were excluded from this study. There were 25 (